Candel Therapeutics stock price target cut to $19 by Stifel on BLA delay
Stifel cut its price target on Candel Therapeutics (CADL) to $19 from $22, citing a delay in the BLA submission timeline to mid-2027. The company is still in discussions with the FDA. Other analysts have maintained or raised their price targets, with Jefferies initiating coverage at $25. CADL shares are up 82% over the past year but are currently trading at $8.39.
How this was made
The 30-second read
Why it matters
The mixed analyst sentiment creates short‑term volatility, with the Stifel downgrade likely driving immediate sell pressure.
Market read
Primary news is the Stifel price‑target reduction, a fresh analyst downgrade that can affect CADL's price today.
What to watch
Cash reserves and recent positive trial data could mitigate downside.
Background
The article reports multiple analyst updates for CADL, highlighting a Stifel target cut and other analysts raising targets after trial data releases.
Ticker impact
Stifel lowered CADL's price target to $19 from $22 due to a delayed BLA submission and reduced commercialization timeline.
downward pressure as the market prices in the reduced target and regulatory delay
Analyst downgrade with a 14% target reduction directly impacts valuation expectations.
Market effects
May weigh on other biotech firms awaiting BLA approvals.
Limited to U.S. biotech sector.
Low global impact.
Counterpoint
Some analysts maintain bullish outlook citing strong pipeline data.
Key entities
- companyCandel Therapeutics Inc.
Biotech firm developing gene‑therapy candidates.
- analystStifel
Equity research firm that cut CADL's price target.
